Comparative effectiveness of statins, metformin, and vitamin D, for prevention of preeclampsia: a systematic review and network meta-analysis of randomized trials - Report - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Efficacy Comparison of Statins, Metformin, and Vitamin D in Preeclampsia Prevention: A Systematic Review and Network Meta-Analysis of Randomized Trials
Clinical Report: Efficacy Comparison of Statins, Metformin, and Vitamin D in Preeclampsia Prevention
Overview
This systematic review and network meta-analysis evaluates the efficacy of statins, metformin, and vitamin D in preventing preeclampsia among high-risk pregnant women. Current preventive measures are limited, with low-dose aspirin being the only recommended intervention for high-risk women.
Background
Preeclampsia is a significant complication of pregnancy, affecting 2%-8% of pregnancies globally and contributing to maternal and perinatal morbidity and mortality. Current preventive measures are limited, with low-dose aspirin being the only recommended intervention for high-risk women.
Data Highlights
No numerical data or trial results were provided in the source material.
Key Findings
Preeclampsia is characterized by hypertension and proteinuria after 20 weeks of gestation.
Current guidelines recommend low-dose aspirin for high-risk women, but its efficacy may be limited to reducing preterm-onset disease.
Pravastatin has shown potential antiangiogenic effects but lacks sufficient evidence for routine use in preventing preeclampsia.
Metformin may reduce the incidence of superimposed pre-eclampsia and improve related risk factors.
Vitamin D supplementation's effect on preeclampsia risk is uncertain, with unclear impacts on neonatal outcomes.
The network meta-analysis aims to provide comparative estimates rather than definitive clinical recommendations due to limited randomized trials.
Clinical Implications
Clinicians should continue to rely on low-dose aspirin as the standard preventive measure for high-risk pregnancies.
Conclusion
Current recommendations remain focused on low-dose aspirin for at-risk populations.
by Menna Alaa El-Khouly, Mazen Mohammed Mahgoub, Mahmoud E. Abd-Elkareem, Noreen M. El-Bayaa, Jana M. Farouk, Mariam M. Fouad, Habiba Mohammed Salah, Ahmed Khaled Saad, Mohammed Al-azab, Rofida Ayman Mohamed, Kholoud Dahshan, Dalia Atef Abouda
